0082N0.KQ Kanaph Therapeutics Inc.
- Market cap
- KRW 119B
- P/E
- -
- P/B
- 2.57x
- ROE
- -41.7%
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0082N0.KQ undervalued?
Graham numberThe Graham number of Kanaph Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kanaph Therapeutics Inc. fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-41.7%), below 10%.
ROA 0/1
Return on assets (-40.0%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-25.8%) is below the industry median (4.8%).
Revenue Growth 1/2
Revenue grew 1.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.8 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.6x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Kanaph Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kanaph Therapeutics Inc.
Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecifi…
Full company profileKanaph Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kanaph Therapeutics Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 5.25B | 348M | 4.25B | 5.56B | 306M |
| Gross Profit | 5.25B | 348M | 4.25B | 5.56B | 306M |
| Operating Income | -11.8B | -10.5B | -4.72B | -4.27B | -20.2B |
| EBITDA | 390M | -8.44B | -22.3B | -30.8B | -19.3B |
| Net Income | -2.92B | -12.6B | -28.3B | -35.6B | -19.3B |
| EPS | -226 | -971 | -2,182 | -2,745 | -1,476 |
| Balance Sheet | |||||
| Total Assets | 7.01B | 20.2B | 20.0B | 15.5B | 48.3B |
| Total Liabilities | 48.2B | 70.4B | 97.7B | 3.08B | 2.02B |
| Shareholders' Equity | -41.2B | -50.1B | -77.7B | 12.4B | 46.3B |
| Cash & Short-term Investments | 4.30B | 7.77B | 8.81B | 1.22B | 10.1B |
| Cash Flow | |||||
| Operating Cash Flow | -7.47B | -8.82B | -3.23B | -7.17B | -12.2B |
| Capital Expenditure | 162M | 1.00B | 70.1M | 77.2M | 92.7M |
| Free Cash Flow | -7.63B | -9.82B | -3.30B | -7.24B | -12.3B |
| Ratios | |||||
| ROE | - | - | - | -287.3% | -41.7% |
| ROA | -41.7% | -62.3% | -141.2% | -230.0% | -40.0% |
| Net Profit Margin | -55.7% | -3,612.0% | -665.0% | -639.5% | -6,312.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Kanaph Therapeutics Inc. dividends
Kanaph Therapeutics Inc. has not paid dividends in the last 4 fiscal years.
Who owns Kanaph Therapeutics Inc.
- Insiders 35.69%
- Institutions 1.00%
- Public & others 63.31%
- Shares outstanding 13.1M
Kanaph Therapeutics Inc. company profile
- Company name
- Kanaph Therapeutics Inc.
- Ticker
- 0082N0.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 3 Itaewon-ro 55-gil, Seoul, South Korea, 04348
- Phone
- 82 2 798 9438
- Website
- kanaphtx.com
About Kanaph Therapeutics Inc.
Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker therapy for patients with wet age-related macular degeneration and geographic atrophy, which has completed preclinical stage; KNP-502, a dual antagonist of the prostaglandin E2 receptors EP2 and EP4 that is in Phase 1 clinical trials to overcome PGE2-mediated immunosuppression within the tumor microenvironment; KNP-503, a SHP2 allosteric inhibitor, which is in preclinical trials for the treatment of various KRAS-mutated cancers, including non-small cell lung cancer, colorectal cancer, and glioblastoma; and KNP-504, a SOS1 inhibitor, which has completed preclinical trials for the treatment of RAS-mutated cancers, including non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and NF1-mutant solid tumor. It also discovers KNP-701, an anti-cMET and anti-EGFR bispecific ADC for treating non-small cell lung cancer. Kanaph Therapeutics Inc. was founded in 2019 and is headquartered in Seoul, South Korea.
Kanaph Therapeutics Inc. management
7- Mr. Byoung Chul Lee Ph.D.CEO & Representative Director · born 1972
- Mr. Changwon ParkExecutive VP, CFO, Head of Business Planning & Inside Director · born 1978
- Mr. Jihoon Chang Ph.D.Executive VP & CTO · born 1971
- Mr. Young Soo Yoon M.B.A., Ph.D.Senior VP, Head of Business Development & CBO · born 1979
- Ms. Hayoun Jung R.Ph.Senior Vice President of Clinical Operations · born 1979
- Mr. Nahm Ju Kim M.S.Senior VP & CMC Manager · born 1977
- Mr. Sungpil Choi R.Ph.Executive VP, CDO, Head of New Drug Development & Inside Director · born 1973